HEARTSCIENCES INC (HSCS)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$3.73+11.01%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
HeartSciences is actively improving its finances with $3.6 million secured in new financing. The company is growing revenue from $0 in 2023-Q4 to a peak of $14,700 in 2025-Q3. Recent M&A activity and a new partnership with North Shore Health boost growth potential. Management is addressing leadership changes to stabilize operations.
HeartSciences remains loss-making with operating income negative $1.9 million in 2026-Q3. Revenue is volatile and low, with no clear upward trend. Executive transitions and capital raises may signal ongoing instability. The company risks failing to improve financial results or secure sustainable growth.
The market currently prices HeartSciences as a loss-making company with uncertain growth, reflected in negative free cash flow yield and no consensus revenue growth estimates. Our view differs by focusing on the potential impact of recent financing and M&A, which are not yet fully reflected in estimates.
Breaks if: revenue falls below $7,350 (half of peak $14,700) by 2026-Q3
Breaks if: additional CEO or COO departures before 2026-Q4
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth scenario. HSCS is currently navigating a volatile management landscape and is loss-making, which adds to its risk profile.
The market appears to have priced in high risk due to the company's ongoing losses and recent operational challenges. Expectations may be low, especially as HSCS has a history of earnings misses.
Fundamentals are likely to remain weak in the near term, as the company has not shown meaningful revenue growth and continues to incur operating losses. The recent changes in risk labeling and consecutive earnings misses add to the uncertainty.
The thesis hinges on several factors, including the successful completion of the merger with Fortitude Mining Holdings and advancements in AI-enabled ECG technology. Additionally, the performance of sector bellwethers and overall economic conditions will play a critical role.
The most important moves since the prior daily snapshot.
No, our read on the company is unchanged. The risk label changed from "high" to "elevated." This indicates a slight improvement in perceived risk. Recent financial performance remains weak compared to its industry peers. There are no new threats or supports affecting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: operating loss worsens beyond -$2.5 million by 2026-Q3
Breaks if: financing falls below $2 million or no new financing by 2026-Q3
Breaks if: no material merger completed by 2026-Q4
Over the next 1 to 3 years, HSCS's outlook is clouded by its current financial struggles and high risk, despite some positive sector momentum. Not investment advice.